This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


Advertisement


 Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Jun. 7, 2013


Advertisement

Advertisement

Advertisement
 

Advertisement


Congratulations to the newest AST board members
In addition to welcoming Dr. Dan Salomon as the AST President, the AST is pleased to welcome three new members to its board: Dr. Larry B. Melton, Ph.D.; Dr. Ronald G. Gill, Ph.D.; and Dr. David P. Nelson. Dr. Kenneth A. Newell, Ph.D., was also voted as president elect. The results of the board of director elections were announced during the Town Hall Meeting at ATC in Seattle on May 20. Welcome to our newest board members, and congratulations to Dr. Newell!
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Advertisement


SOCIETY NEWS


Recognizing excellence
The AST Achievement Awards recognize AST members who have made significant contributions to the field of transplantation as investigators, advocates, mentors and more. This year, the AST was pleased to recognize 10 individuals. Click here to read about this year's recipients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  University of Utah - Multi-Organ Transplant Surgeon
The University Of Utah Department Of Surgery is seeking applications for a faculty member to join the multi-organ transplant team at the assistant professor level. This is an opportunity to join an expanding program and a cohesive group of transplant surgeons focused on excellence. The candidate should be board certified in general surgery and have completed an ASTS approved transplantation surgery fellowship. Apply here
 


Save the date for AST's Cutting Edge of Transplantation 2014
Are we on the right track with new drugs and biologics? Have the targets changed? Where can we really impact outcomes with "technology-omics?" The time has come to integrate our strategies, therapies and technology, and critically assess their merits as we face the enormous task of extending transplant survival. Save the date for the 2014 AST Cutting Edge of Transplantation, where expert clinicians, leading diagnosticians and world class scientists will address this enormous challenge together with an engaged audience.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Encouraging breakthroughs in transplantation
The AST is proud to have a long history of supporting research in the field of transplantation. This year, the AST, together with its corporate supporters, awarded $480,000 in research grants to a talented pool of seven investigators. Click here to read more about the grant recipients and their research.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


Webinar June 12: The Need for Resources: Approaching Senior Management — free to AST members
"The Need for Resources: Approaching Senior Management" is part of the Business of Transplantation webinar series and airs at 2 p.m. EST on Wednesday, June 12. Click here to register in advance; it's free for AST members and available for a small fee to non-members. Archives of webinars from November 2012-May 2013 are also available.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Featured Advertisers


Advertisement
Astellas Pharma US, Inc.

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to changing tomorrow by improving the health of people around the world through innovative and reliable pharmaceutical products. For more information about Astellas Pharma US, Inc., please visit our Web site at www.astellas.us
Advertisement
New LIFECODES SSO Typing Kits

LIFECODES is introducing its new HLA-SSO kits. The new kit includes a validated, high-performance enzyme for improved reliability and performance with the continued ease of no centrifugation or wash steps; providing accurate, clear and easy to interpret results.
Advertisement
Genzyme


Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. MORE


TRANSPLANT NEWS


Blood tests OK for fibrosis diagnosis in hepatitus C
MedPage Today
Blood testing can accurately identify clinically significant fibrosis and cirrhosis in people with hepatitis C virus (HCV) infection and may be an alternative to liver biopsy in some patients, a new study found. The analysis of 172 studies comparing various blood tests to biopsy in HCV patients revealed that some of the simplest, cheapest blood tests performed as well as more expensive, complex tests, reported Dr. Roger Chou, and Ngoc Wasson, MPH, from the Evidence-Based Practice Center at Oregon Health and Science University in Portland.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Amnion-derived multipotent progenitor cells support allograft tolerance induction
American Journal of Transplantation (login required)
Donor-specific immunological tolerance using high doses of bone marrow cells (BMCs) has been demonstrated in mixed chimerism-based tolerance induction protocols; however, the development of graft versus host disease remains a risk. Here, researchers demonstrate that the co-infusion of limited numbers of donor unfractionated BMCs with human amnion-derived multipotent progenitor cells (AMPs) seven days post–allograft transplantation facilitates macrochimerism induction and graft tolerance in a mouse skin transplantation model. AMPs + BMCs co-infusion with minimal conditioning led to stable, mixed, multilineage lymphoid and myeloid macrochimerism, deletion of donor-reactive T cells, expansion of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and long-term allograft survival (>300 days). It has been speculated that AMPs maybe a pro-tolerogenic cellular therapeutic that could have clinical efficacy for both solid organ and hematopoietic stem cell transplant applications.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


Pulmonary hypertension in renal disease: Epidemiology, potential mechanisms and implications.
NCBI
Pulmonary hypertension (PH) is highly prevalent in end-stage renal disease. Several observational studies, based on an echocardiographic diagnosis of PH, have suggested a prevalence of 30-60% and an association with increased mortality and poorer outcome following renal transplantation. The pathogenesis of PH in this population remains poorly understood. Reported associations include arteriovenous fistulae, cardiac dysfunction, fluid overload, bone mineral disorder and non-biocompatible dialysis membranes.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Infection, cardiovascular disease more prevalent among liver transplant recipients with metabolic syndrome
Healio
The presence of metabolic syndrome post-liver transplantation increased the risk for infection and cardiovascular disease, according to data presented at Digestive Disease Week. In a retrospective cohort study, researchers evaluated 158 patients who underwent liver transplantation between 2002 and 2007 at a single medical facility, with follow-up through September 2012. The presence of metabolic syndrome (MetS) before transplant and at six and 12 months post-transplant was determined in each case.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Featured Advertisers


Advertisement
Put Science on Your Side

Drug Monitoring Platforms since 1981.

Learn More
Advertisement
Exclusively Focused Transplant Pharmacy Therapeutics
Transplant IV Biologics and Oral Immunosuppressives specializing in Desensitization and AMR Treatment and Prevention. MORE


Cytomegalovirus infection post-pancreas-kidney transplantation — results of antiviral prophylaxis in high-risk patients
Clinical Transplantation (login required)
Cytomegalovirus (CMV) is a major pathogen affecting solid organ transplant (SOT) recipients. Prophylactic strategies have decreased the rate of CMV infection/disease among SOT. However, data on the effect of current prophylactic strategies for simultaneous pancreas–kidney (SPK) or pancreas after kidney (PAK) transplant remain limited. In a recent review, researchers report their experience of CMV prophylaxis in SPK/PAK recipients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Change in immunosuppressive regimen, hemodynamic and inflammatory markers of cardiovascular disease after kidney transplantation
NCBI
Although rejection rates and short-term graft survival have significantly improved in kidney transplantation with the introduction of calcineurin inhibitor (CNI), cardiovascular disease (CVD) and metabolic complications are being increasingly recognized as important causes of morbidity and mortality. We hypothesize that non-CNI proliferation signal inhibitor (PSI)-based immunosuppressive regimen is associated with improved arterial stiffness after kidney transplantation compared with CNI-based immunosuppressive regimens.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    UDiscarded human kidneys as a source of ECM scaffold for kidney regeneration technologies (NCBI)
Trial: Tacrolimus plus mycophenolate mofetil vs. cyclosporine plus everolimus in deceased donor kidney transplant recipients (Clinical Transplantation)
Plasmacytoid dendritic cells: No longer an enigma and now key to transplant tolerance? (American Journal of Transplantation)

Don't be left behind. Click here to see what else you missed.


Kids with new hearts often skip meds
MedPage Today
Among pediatric heart transplant recipients, failure to adhere to immunosuppressive medication is relatively common and is associated with a high mortality rate, researchers found. Over a seven-year period, 9 percent of heart transplant recipients younger than 18 were non-adherent at least once, which set back his or her recovery, according to Dr. Christopher Almond, MPH, of Boston Children's Hospital, and colleagues.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The effectiveness of the combination of rituximab and high-dose immunoglobulin in the immunomodulation of sensitized kidney transplant candidates
Clinical Transplantation (login required)
Kidney transplantation faces many challenges not the least of which is the presence of pre-formed HLA antibodies. At our institution, we have used a combination of methods to immunomodulate sensitized patients. Most recently, this has been attempted with a combination of immunoglobulin (IVIG) and rituximab.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
May 31, 2013
May 24, 2013
May 10, 2013
May 10, 2013






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063